Curcumin: The story so far

European Journal of Cancer

Volumn 41, Issue 13, 2005, Pages 1955-1968

  Sharma, R A ^a,b   Gescher, A J ^a   Steward, W P ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Carcinogenesis; Chemoprevention; Colorectal cancer

Indexed keywords

CELL ENZYME; CURCUMIN; GLUTATHIONE TRANSFERASE; PROSTAGLANDIN SYNTHASE;

ACIDITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL ADHESION; CLINICAL TRIAL; COLON CANCER; CURCUMA LONGA; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; DRUG SAFETY; GASTROINTESTINAL TRACT; GENETIC TRANSCRIPTION; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SPICE;

EID: 27144545998     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.05.009     Document Type: Article

References (126)

1. Brouk B. Plants consumed by man. New York, Academic Press, 1975., p. 331.
2. Eigner D, Sholz D. Ferula asa-foetida and curcuma longa in traditional medical treatment and diet in Nepal. J Ethnopharmacol 1999, 67, 1-6.
3. Milobedzka J, Kostanecki V, Lampe V. Structure. Chem Ber 1910, 43, 2163.
4. Heath DD, Khwaja F, Rock CL. Curcumin content of turmeric and curry powders. FASEB J 2004, 18, A125.
5. Ammon HP, Wahl MA. Pharmacology of curcuma longa. Planta Med 1991, 57, 1-7.
6. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23, 363-398.
7. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin - cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 2004, 44, 97-111.
8. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997, 15, 1867-1876.
9. Jovanovic SV, Steenken S, Boone CW, et al. H-Atom transfer is a preferred antioxidant mechanism of curcumin. J Am Chem Soc 1999, 121, 9677-9681.
10. Lin JK, Pan MH, Shiau SYL. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 2000, 13, 153-158.
11. Tonnesen HH, Karlsen J. Studies on curcumin and curcuminoids: VI - kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch 1985, 180, 402-404.
12. Tonnesen HH, Karlsen J, van Henegouwen GB. Studies on curcumin and curcuminoids: VIII - photochemical stability of curcumin. Z Lebensm Unters Forsch 1986, 183, 116-122.
13. Huang MT, Ma W, Lu YP, et al. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydro-curcumin on 12-O-tetradecanoylphorbol-13- acetate-induced tumor promotion. Carcinogenesis 1995, 16, 2493-2497.
14. Sreejayan R, Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 1994, 46, 1013-1016.
15. Mau JL, Lai EYC, Wang NP, et al. Composition and antioxidant activity of the essential oil from Curcuma zedoaria. Food Chem 2003, 82, 583-591.
16. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol 1978, 43, 86-92.
17. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicol 1980, 16, 259-265.
18. Ravindranath V, Chandrasekhara N. Metabolism of curcumin-studies with 3H curcumin. Toxicol 1981, 22, 337-344.
19. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3, 5-dione in the rat. Xenobiotica 1978, 8, 761-768.
20. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicol 1981, 20, 251-257.
21. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Met Dispos 1999, 27, 486-494.
22. 2 production. Cancer Res 2001, 61, 1058-1064.
23. Ireson CR, Jones DJL, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidem Biomar Prevent 2002, 11, 97-104.
24. Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of dietary curcumin on glutathione S-transferase and malondi-aldehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 2001, 7, 1452-1458.
25. Shoba G, Joy D, Joseph T, et al. Influence of pipeline on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998, 64, 353-356.
26. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21, 2895-2900.
27. Ruffin MT, Normolle DP, Heath DD, et al. Dose escalation of curcumin in healthy adults. Cancer Epidem Biomar Prevent 2003, 12(Part 2 Suppl. S), 1324S.
28. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer, Clin Cancer Res 2001, 7, 1894-1900.
29. Sharma RA, Euden SA, Platten SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10, 6847-6854.
30. Garcea G, Berry DP, Jones DJL, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidem Biomar Prevent 2005, 14, 120-125.
31. Garcea G, Jones DJL, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004, 90, 1011-1015.
32. NCI, DCPC. Clinical development plan: curcumin. J Cell Biochem 1996, 26S, 72-85.
33. Gupta B, Kulshrestha CK, Sristava RK, et al. Mechanisms of curcumin induced gastric ulcer in rats. Indian J Med Res 1980, 71, 806-814.
34. Perkins S, Verschoyle RD, Hill KA, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidem Biomar Prevent 2002, 11, 535-540.
35. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980, 71, 632-634.
36. Chan MM, Huang HI, Fenton MR, et al. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 1998, 55, 1955-1962.
37. Pereira MA, Grubbs CJ, Barnes, et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenzaanthracene-induced mammary cancer in rats. Carcinogenesis 1996, 17, 1305-1311.
38. Hanif R, Qiao L, Shiff SJ, et al. Curcumin, a natural plant phenolic food additive inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 1997, 130, 576-584.
39. Chen H, Zhang ZS, Zhang YL, et al. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cell lines. Anticancer Res 1999, 19, 3675-3680.
40. Mori H, Niwa K, Zhang Q, et al. Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial Carcinogenesis model and on an in vitro model in human colorectal cells. Mutat Res Fund Mol Mech 2001, 480, 201-207.
41. Jiang MC, Yang Yen HF, Yen JJY, et al. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer 1996, 26, 111-120.
42. Simon A, Allais DP, Duroux JL, et al. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett 1998, 129, 111-116.
43. Gautam SC, Yong YX, Pndolia KR, et al. Nonselective inhibition of proliferation of transformed and nontransformed cells by the anticancer agent curcumin (diferuloylmethane). Biochem Pharmacol 1998, 55, 1333-1337.
44. Plummer S, Wakelin D, Bouer M, et al. Inhibition of growth of colon tumour cells by curcumin correlates with inhibition of the IkB kinase and down regulation of cyclin D1. Br J Cancer 2000, 83(Suppl. 1), 20.
45. Han SS, Chung ST, Robertson DA, et al. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 1999, 93, 152-161.
46. Bhaumik S, Jyothi MD, Khar A. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett 2000, 483, 78-82.
47. Yan CH, Jamaluddin MS, Aggarwal B, et al. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 2005, 4, 233-241.
48. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer - I. Prostate Cancer Dis 2000, 3, 84-93.
49. Chen AP, Xu J. Activation of PPAR gamma by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol 2005, 288, G447-G456.
50. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1996, 1317, 95-100.
51. Ozaki K, Kawata Y, Amano S, et al. Stimulatory effect of curcumin on osteoclast apoptosis. Biochem Pharmacol 2000, 59, 1577-1581.
52. Tsvetkov P, Asher G, Reiss V, et al. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA 2005, 102, 5535-5540.
53. Chendil D, Ranga RS, Meigooni D, et al. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004, 23, 1599-1607.
54. Baatout S, Derradji H, Jacquet P, et al. Effect of curcuma on radiation-induced apoptosis in human cancer cells. Int J Oncol 2004, 24, 321-329.
55. Inano H, Onoda M. Radioprotective action of curcumin extracted from Curcuma longa Linn. Int J Radiat Oncol Biol Phys 2002, 53, 735-743.
56. Sharma A, Gautam S, Jadhav SS. Spice extracts as dose-modifying factors in radiation inactivation of bacteria. J Agric Food Chem 2000, 48, 1340-1344.
57. Dahl TA, McGowan WM, Shand MA, et al. Photokilling of bacteria by the natural dye curcumin. Arch Microbiol 1989, 151, 183-185.
58. Tsao SM, Yin MC. Enhanced inhibitory effect from interaction of curcumin with amphotericin B or fluconazole against candida species. J Food Drug Anal 2000, 8, 208-212.
59. de Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev 2000, 20, 323-349.
60. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 1991, 88, 5292-5296.
61. Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998, 17, 173-178.
62. Scott DW, Loo G. Curcumin-induced GADD153 gene upregulation in human colon cancer cells. Carcinogenesis 2004, 25, 2155-2164.
63. Gao X, Kuo J, Jiang H, et al. Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity and cytokine production in vitro. Biochem Pharmacol 2004, 68, 51-61.
64. Morin D, Barthelemy S, Zini R, et al. Curcumin induces the mithochondrial permeablility transition pore mediated by membrane protein thiol oxidation. FEBS Lett 2001, 495, 131-136.
65. Jana NR, Dikshit P, Goswami A, et al. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 2004, 279, 11680-11685.
66. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995, 55, 259-266.
67. Sharma RA, Farmer PB. Biological relevance of adduct detection to the chemoprevention of cancer. Clin Cancer Res 2004, 10, 4901-4912.
68. Kawamori T, Lubet R, Steele VE, et al. Chemopreventative effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999, 59, 597-601.
69. Mahmoud NN, Carothers AM, Grunberger D, et al. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 2000, 21, 921-927.
70. Samaha HS, Kelloff GJ, Steele V, et al. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997, 57, 1301-1305.
71. Luongo C, Moser AR, Gledhill S, et al. Loss of Apc(+) in intestinal adenomas from Min mice. Cancer Res 1994, 54, 5947-5952.
72. Conney AH. Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the seventh DeWitt S. Goodman Lecture. Cancer Res 2003, 63, 7005-7031.
73. Li N, Chen X, Liao J, et al. Inhibition of 7,12-dimethyl-benzaanthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 2002, 23, 1307-1313.
74. Khafif A, Schantz SP, Chou TC, et al. Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 1998, 19, 419-424.
75. Liu Y, Chang RL, Cui XX, et al. Synergistic effects of curcumin on all-trans retinoic acid- and 1 alpha, 25-dihydroxyvitamin D3-induced differentiation in human promyelocytic leukaemia HL-60 cells. Oncol Res 1997, 9, 19-29.
76. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004, 304, 600-602.
77. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998, 90, 1609-1620.
78. Sharma RA. Translational medicine: targetting cyclooxygenase isozymes to prevent cancer. Quart J Med 2002, 95, 267-273.
79. Zhang F, Altorki NK, Mestre JR, et al. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol estertreated human gastrointestinal epithelial cells. Carcinogenesis 1999, 20,445-451.
80. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene 1999, 18, 6013-6020.
81. Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998, 396, 77-78.
82. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93, 705-716.
83. Gescher A, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol 2001, 2, 371-379.
84. Firozi PF, Aboobaker VS, Bhattacharya RK. Action of curcumin on the cytochrome P450-system catalyzing the activation of aflatoxin B1. Chem-Biol Interact 1996, 100, 41-51.
85. Ciolino HP, Daschner PJ, Wang TT, et al. Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol 1998, 56, 197-206.
86. Singh SV, Hu X, Srivastava SK, et al. Mechanism of inhibition of benzoapyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis 1998, 19, 1357-1360.
87. Susan M, Rao MNA. Induction of glutathione S-transferase activity by curcumin in mice. Drug Res 1992, 42, 962-964.
88. Piper JT, Singhal SS, Salameh M, et al. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 1998, 30, 445-456.
89. Nijhoff WA, Groen GM, Peters WHM. Induction of rat hepatic and intestinal glutathione S-transferases and glutathione by dietary naturally occurring anticarcinogens. Int J Oncol 1993, 3, 1131-1139.
90. Dinkova-Kostova AT, Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 1999, 20, 911-914.
91. Hayes JD, Pulford DJ. The glutathione S-transferases supergene family. Crit Rev Biochem Mol Biol 1995, 30, 445-600.
92. Duvoix A, Delhalle S, Blasius R, et al. Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. Biochem Pharmacol 2004, 68, 1101-1111.
93. Joe B, Lokesh BR. Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta 1994, 1224, 255-263.
94. Tonnesen HH, Greenhill JV. Studies on curcumin and curcuminoids. XXII. Curcumin as a reducing agent and as a radical scavenger. Int J Pharmaceut 1992, 87, 79-87.
95. Kunchandy E, Rao MNA. Oxygen radical scavenging activity of curcumin. Int J Pharmaceut 1990, 58, 237-240.
96. Reddy AC, Lokesh BR. Studies on anti-inflammatory activity of spice principles and dietary n-3 polyunsaturated fatty acids on carrageenan-induced inflammation in rats. Ann Nutr Met 1994, 38, 349-358.
97. Ahsan H, Parveen N, Khan NU, et al. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem-Biol Interact 1999, 121, 161-175.
98. Nair J, Strand S, Frank N, et al. Apoptosis and age-dependant induction of nuclear and mitochondrial etheno-DNA adducts in Long-Evans Cinnamon (LEC) rats: enhanced DNA damage by dietary curcumin upon copper accumulation. Carcinogenesis 2005, 26, 1307-1315.
99. Lala PK, Chakraborty C. Role of nitric oxide in Carcinogenesis and tumour progression. Lancet Oncol 2001, 2, 149-156.
100. deRojas-Walker T, Tamir S, Ji H, et al. Nitric oxide induces oxidative damage in addition to deaminiation in macrophage DNA. Chem Res Toxicol 1995, 8, 473-477.
101. 6-methylguanine-DNA-methyltransferase. Carcinogenesis 1994, 15, 443-447.
102. Graziewicz M, Wink DA, Laval F. Nitric oxide inhibits DNA ligase activity: potential mechanisms for NO-mediated DNA damage. Carcinogenesis 1996, 17, 2501-2505.
103. Ambs S, Bennett WP, Merrium WG, et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999, 91, 86-88., reply 1510-1511.
104. von Knethen A, Brune B. Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis. FASEB J 1997, 11, 887-895.
105. von Knethen A, Callsen D, Brune B. NF-kB and AP-1 activation by nitric oxide attenuated apoptotic death in RAW 264.7 macrophages. Mol Biol Cell 1999, 10, 361-370.
106. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 1995, 206, 533-540.
107. Greene HSN. Heterologous transplantation of mammalian tumors. The transfer of human tumors to alien species. J Exp Med 1941, 73, 461-486.
108. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333, 1757-1763.
109. Sharma RA, Harris AL, Dalgleish AG, et al. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol 2001, 2, 726-732.
110. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998, 4, 376-383.
111. Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ 1998, 9, 305-312.
112. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett 1999, 141, 159-165.
113. Chan MMY. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995, 49, 1551-1556.
114. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999, 39, 41-47.
115. Gupta B, Ghosh B. Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells, Int J Immnopharmacol 1999, 21, 745-757.
116. Jaiswal AS, Marlow BP, Gupta N, et al. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuloylmethane)-induced growth arrest and apopstosis in colon cancer cells. Oncogene 2002, 21, 8414-8427.
117. Raysid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 1999, 13, 245-249.
118. Plummer SM, Hill KA, Festing MFW, et al. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 2001, 10, 1295-1299.
119. Kim HY, Park EJ, Joe EH, et al. Curcumin suppresses janus kinase-STAT inflammatory signalling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol 2003, 171, 6072-6079.
120. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003, 171, 3863-3871.
121. Sugimoto K, Hanai H, Tozawa K, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterol 2002, 123, 1912-1922.
122. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with post-operative inflammation. Int J Clin Pharmacol Ther Toxicol 1986, 24, 651-654.
123. Lal B, Kapoor AK, Asthana OP, et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res 1999, 13, 318-322.
124. Lal B, Kapoor AK, Agrawal Pk, et al. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res 2000, 14, 443-447.
125. Martin-Cordero C, Lopez-Lazaro M, Galvez M, et al. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib Med Chem 2003, 18, 505-509.
126. Kuttan R, Sudheeran PC, Josph CD. Turmeric and curcumin as topical agents in cancer therapy. Tumori 1987, 73, 29-31.